CN104095236B - A kind of have health care oral liquid of whitening and delaying senility function and preparation method thereof - Google Patents
A kind of have health care oral liquid of whitening and delaying senility function and preparation method thereof Download PDFInfo
- Publication number
- CN104095236B CN104095236B CN201410348555.5A CN201410348555A CN104095236B CN 104095236 B CN104095236 B CN 104095236B CN 201410348555 A CN201410348555 A CN 201410348555A CN 104095236 B CN104095236 B CN 104095236B
- Authority
- CN
- China
- Prior art keywords
- oral liquid
- health care
- whitening
- care oral
- delaying senility
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 62
- 230000036541 health Effects 0.000 title claims abstract description 29
- 230000002087 whitening effect Effects 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims description 8
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims abstract description 26
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229940030275 epigallocatechin gallate Drugs 0.000 claims abstract description 26
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 24
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 claims abstract description 17
- 229940093767 glabridin Drugs 0.000 claims abstract description 17
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 claims abstract description 17
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229930006000 Sucrose Natural products 0.000 claims abstract description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 8
- 239000008367 deionised water Substances 0.000 claims abstract description 8
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 8
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 claims abstract description 8
- 235000012907 honey Nutrition 0.000 claims abstract description 8
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims abstract description 8
- 235000010234 sodium benzoate Nutrition 0.000 claims abstract description 8
- 239000004299 sodium benzoate Substances 0.000 claims abstract description 8
- 239000005720 sucrose Substances 0.000 claims abstract description 8
- 238000011049 filling Methods 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 230000003078 antioxidant effect Effects 0.000 abstract description 6
- 239000003963 antioxidant agent Substances 0.000 abstract description 5
- 235000006708 antioxidants Nutrition 0.000 abstract description 5
- 208000008589 Obesity Diseases 0.000 abstract description 4
- 230000003712 anti-aging effect Effects 0.000 abstract description 4
- 230000008859 change Effects 0.000 abstract description 4
- 235000020824 obesity Nutrition 0.000 abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 201000001429 Intracranial Thrombosis Diseases 0.000 abstract description 3
- 208000034189 Sclerosis Diseases 0.000 abstract description 3
- 230000009471 action Effects 0.000 abstract description 3
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- 230000000259 anti-tumor effect Effects 0.000 abstract description 3
- 230000000840 anti-viral effect Effects 0.000 abstract description 3
- 210000001367 artery Anatomy 0.000 abstract description 3
- 201000011510 cancer Diseases 0.000 abstract description 3
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 3
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 230000006870 function Effects 0.000 description 15
- 239000003814 drug Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 8
- 230000032683 aging Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000005013 brain tissue Anatomy 0.000 description 6
- 230000003064 anti-oxidating effect Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 229930194248 Licoflavone Natural products 0.000 description 4
- MEHHCBRCXIDGKZ-UHFFFAOYSA-N Licoflavone C Natural products CC(C)=CCC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 MEHHCBRCXIDGKZ-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000002000 scavenging effect Effects 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- COLMVFWKLOZOOP-UHFFFAOYSA-N Glabrone Chemical compound OC1=CC=C2C(=O)C(C3=CC=C4OC(C=CC4=C3O)(C)C)=COC2=C1 COLMVFWKLOZOOP-UHFFFAOYSA-N 0.000 description 2
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000036564 melanin content Effects 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940035423 ethyl ether Drugs 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- -1 flavonoids polyphenol Chemical class 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000003674 kinase activity assay Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 230000003617 peroxidasic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940026510 theanine Drugs 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/56—Flavouring or bittering agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of health care oral liquid with whitening and delaying senility function, it is characterized in that, comprise following component and the mass percentage of each component is respectively: glabridin: 0.5 ~ 1%; Epigallo-catechin gallate (EGCG): 0.5%-1%; Natrium citricum: 0.05 ~ 0.15%; Citric acid: 0.2 ~ 0.4%; Honey: 8 ~ 12%; Sucrose: 4%; Sodium Benzoate: 0.05%; Deionized water: surplus.The present invention by with the addition of the component such as glabridin and Epigallo-catechin gallate (EGCG) in health care oral liquid, makes health care oral liquid have whitening, anti-oxidant, removes interior free yl, antitumor, anti-sudden change, anti-ageing, anti-inflammatory, a series of BA such as antiviral, to prevention and therapy malignant tumour, hyperlipemia, artery sclerosis, cerebral thrombus, diabetes, obesity etc. all have good action.
Description
Technical field
The present invention relates to a kind of health care oral liquid and preparation method thereof, especially relate to and a kind of there is health care oral liquid of whitening and delaying senility function and preparation method thereof, belong to traditional Chinese medicine health care product technical field.
Background technology
Doctor trained in Western medicine whitening many employings external therapy is attached most importance to take stopgap measures, though effective in cure fast advantage, toxic and side effect is obvious, and curative effect is very unstable.Chinese medicine whitening is treated because adopting interior tune method, and to effect a permanent cure, toxic and side effect is little, and curative effect is also relatively stable.Chinese medicine whitening spot-removing is one of important content of Chinese medicine beauty treatment, also be an important component part of Chinese medical, Chinese medicine whitening, be exactly under instruction of Chinese Medicine theory, use Chinese medicine conditioning viscera, Yin Yang balancing, to reach the object of whitening, there is dividing of activating blood and removing stasis Method, dispersing stagnated hepatoqi method, temperature male wind-supplying kidney method.
Summary of the invention
In order to overcome the deficiencies in the prior art, the object of the present invention is to provide a kind of use safety, what effect was lasting has health care oral liquid of whitening and delaying senility function and preparation method thereof.
The present invention is achieved through the following technical solutions:
There is a health care oral liquid for whitening and delaying senility function, it is characterized in that, comprise following component and the mass percentage of each component is respectively:
Glabridin: 0.5 ~ 1%;
Epigallo-catechin gallate (EGCG): 0.5%-1%;
Natrium citricum: 0.05 ~ 0.15%;
Citric acid: 0.2 ~ 0.4%;
Honey: 8 ~ 12%;
Sucrose: 4%;
Sodium Benzoate: 0.05%;
Deionized water: surplus.
Above-mentioned a kind of preparation method with the health care oral liquid of whitening and delaying senility function, is characterized in that, comprise the following steps:
(1) mix: by glabridin: 0.5 ~ 1%; Epigallo-catechin gallate (EGCG): 0.5%-1%; Natrium citricum: 0.05 ~ 0.15%; Citric acid: 0.2 ~ 0.4%; Honey: 8 ~ 12%; Sucrose: 4%; Sodium Benzoate: 0.05%; Deionized water: after surplus mixing, stir, and by homogenizer homogeneous;
(2) filling: by filling according to the amount of every bottle of 10ml for the mixture liquid after step (1) homogeneous;
(3) sterilization: after the liquid after filling for step (2) is adopted pasteurize, keep 40min under the temperature conditions of 70 ~ 80 DEG C after, obtain the health care oral liquid with whitening and delaying senility function.
The invention has the beneficial effects as follows: the present invention by with the addition of the component such as glabridin and Epigallo-catechin gallate (EGCG) in health care oral liquid, makes health care oral liquid have whitening, anti-oxidant, removes interior free yl, antitumor, anti-sudden change, anti-ageing, anti-inflammatory, a series of BA such as antiviral, to prevention and therapy malignant tumour, hyperlipemia, artery sclerosis, cerebral thrombus, diabetes, obesity etc. all have good action.
Accompanying drawing explanation
Fig. 1 is the determination test design sketch that health care oral liquid suppresses tyrosine kinase activity;
Fig. 2 is the determination test design sketch of health care oral liquid antioxidation activity;
Fig. 3 is experimenter's melanocyte changing trend diagram.
Detailed description of the invention
Below in conjunction with specific embodiments, the present invention is described in detail:
The Fang Yi with the health care oral liquid of whitening and delaying senility function of the present invention is analyzed as follows:
Glabridin is except being a kind of natural whitening additive, research also proves, the edible licoflavone containing glabridin has many benefits to human body: 1. it has antiatherogenic effect: this is because the glabridin in licoflavone can the oxidation of LDL of T suppression cell induction and atherosclerotic development, reduces human body LDL value thus; 2. scavenging free radicals and antihemolysis: glycyrrhizin and glabrone demonstrate the activity of significant scavenging activated oxygen; Therefore contribute to reducing cholesterol, promote cardiovascular health, have protective effect to respiratory system; 3. hepatoprotective effect: the damage that the liver cell fine structure caused by ethanol can be protected, relevant with scavenging free radicals; 4. antitumaous effect; 5. suppress by radiation-induced peroxidatic reaction of lipid.
Above-mentioned these are all because flavonoids polyphenol contained in licoflavone is effective antioxidant, and its antioxidation activity is that solid foundation has been established in its application in healthcare products, cosmetics etc., also show boundless application prospect.
Simultaneously, glabridin can also reduce obesity, the clinical report of animals and humans shows, glabridin is a kind of for preventing body fat, especially the too much method safely and effectively of visceral fat accumulation, report also shows, glabridin can lose weight, reduce waistline, and contribute to keeping normal blood sugar level simultaneously, in addition, glabridin also can stimulate the activity of esterlysis enzyme or combustion lipase in liver, the eubolism of body weight of keeping fit and fat, licoflavone also can slow down the aging of brain, and keeps brain sharp.
Epigallo-catechin gallate (EGCG) (EGCG) is a kind of active ingredient extracted from Chinese green tea; it is the main activity of green tea and water-soluble components; it is the component that in catechin, content is the highest; because have special stereochemical structure; EGCG has very strong antioxidation activity, and its antioxidation activity is at least ascorbic more than 100 times, is 25 times of vitamin E; can Cell protection and DNA from infringement, in anticancer and angiocardiopathy, act as important role.Research shows, EGCG has anti-oxidant significantly, removes interior free yl, antitumor, anti-sudden change, anti-ageing, anti-inflammatory, a series of BA such as antiviral, to prevention and therapy malignant tumour, hyperlipemia, artery sclerosis, cerebral thrombus, diabetes, obesity etc. all have good action.
Natural ester catechin research and development is the nineties, and its application study starts from antioxidant.Along with going deep into of research, open up cosmetics, daily use chemicals, gently changed, refined, medicine and many-sided application such as health care.High purity EGCG, compared with common tea polyphenol extract thing, has active ingredient clear and definite, does not have the advantages such as impurity side effect is disturbed, and activity is stronger.
Embodiment 1
Prepare the health care oral liquid with whitening and delaying senility function of the present invention to comprise the following steps:
(1) mix: by glabridin: 0.5g; Epigallo-catechin gallate (EGCG): 0.5g; Natrium citricum: 0.05g; Citric acid: 0.2g; Honey: 8g; Sucrose: 4g; Sodium Benzoate: 0.05g; Deionized water: 86.7g stirs after mixing, and by homogenizer homogeneous;
(2) filling: by filling according to the amount of every bottle of 10ml for the mixture liquid after step (1) homogeneous;
(3) sterilization: after the liquid after filling for step (2) is adopted pasteurize, keep 40min under the temperature conditions of 75 DEG C after, obtain the health care oral liquid with whitening and delaying senility function.
Embodiment 2
Prepare the health care oral liquid with whitening and delaying senility function of the present invention to comprise the following steps:
(1) mix: by glabridin: 1g; Epigallo-catechin gallate (EGCG): 1g; Natrium citricum: 0.15g; Citric acid: 0.4g; Honey: 12g; Sucrose: 4g; Sodium Benzoate: 0.05g; Deionized water: 81.4g stirs after mixing, and by homogenizer homogeneous;
(2) filling: by filling according to the amount of every bottle of 10ml for the mixture liquid after step (1) homogeneous;
(3) sterilization: after the liquid after filling for step (2) is adopted pasteurize, keep 40min under the temperature conditions of 75 DEG C after, obtain the health care oral liquid with whitening and delaying senility function.
Embodiment 3
Prepare the health care oral liquid with whitening and delaying senility function of the present invention to comprise the following steps:
(1) mix: by glabridin: 0.75g; Epigallo-catechin gallate (EGCG): 075g; Natrium citricum: 0.1g; Citric acid: 0.3g; Honey: 10g; Sucrose: 4g; Sodium Benzoate: 0.05g; Deionized water: 84.3g stirs after mixing, and by homogenizer homogeneous;
(2) filling: by filling according to the amount of every bottle of 10ml for the mixture liquid after step (1) homogeneous;
(3) sterilization: after the liquid after filling for step (2) is adopted pasteurize, keep 40min under the temperature conditions of 75 DEG C after, obtain the health care oral liquid with whitening and delaying senility function.
Confirmatory experiment one: health care oral liquid suppresses the mensuration of tyrosine kinase activity
Suppress tyrosine kinase activity assay method to be prior art, do not repeat them here.Measurement result is shown in Fig. 1, and oral liquid suppresses the IC50=0.14mg/ml of EGFR-TK, and it suppresses tyrosine kinase activity suitable with ursin (IC50=0.16mg/ml).
Confirmatory experiment two: the mensuration of health care oral liquid antioxidation activity
Antioxidative Activity Determination is prior art, also repeats no more at this, and measurement result is shown in Fig. 2, and the IC50=0.011mg/ml of DPPH removed by oral liquid, and the activity of its scavenging free radicals is suitable with Vc ethylether (IC50=0.017mg/ml).
Confirmatory experiment three: oral liquid is studied the anti-aging effects of D-galactolipin mice aging model
(1) material
Healthy Kunming mouse 50, in age in male and female half and half, 4-5 week, body weight is 20 ± 2g, is provided by Shanghai Slac Experimental Animal Co., Ltd..Galactolipin (traditional Chinese medicines) becomes 5% concentration with the normal saline of sterilizing.Superoxide dismutase (SOD), MDA (MDA) build up Bioengineering Research Institute purchased from Nanjing.
(2) model preparation
Mouse weights is also divided into 5 groups at random: Normal group, aging model group, the basic, normal, high dosage group of oral liquid.It is oral that Normal group gives distilled water, simultaneously at the physiological saline of neck hypodermic injection sterilizing; It is oral that aging model group gives distilled water; Oral liquid group gives 25,50 and 100mg/kg (basic, normal, high dosage) oral liquid (gastric infusion respectively, every day 1 time, continuous 50 days), simultaneously at the D-galactolipin 0.2ml (every day 1 time, continuous 50 days) of mouse neck hypodermic injection 5%.Experimental session mouse freely ingests and drinks water, and records body weight 1 time weekly.The experiment end of term carries out learning and memory test, gets brain tissue subsequently and weighs and measure biochemical indicator.
(3) electric maze method test learning and memory of little mouse achievement
Learning and memory of little mouse is determined in Y type labyrinth box and carries out, and is put into by mouse by initial arm, and mouse is free movable 8min in 3 arms.The order that in record 8min, every mouse is shuttled back and forth at each arm also calculates mouse in 5min and 8min respectively and correctly to shuttle back and forth the percentage of order.
(4) mensuration of Mice brain tissues biochemical indicator
Give D-galactolipin and theanine 50 days and after carrying out learning and memory attainment test, mouse breaks end, and is separated brain tissue rapidly, washes 2 times with ice-cold phosphate buffer (PBS), the tissue homogenate making 10% is for the mensuration of various biochemical indicator.With the protein content of Coomassie brilliant blue improved method tissue homogenate.Xanthine oxidase is adopted to measure SOD respectively active, thiobarbituricacidα-colorimetric method for determining MDA content.
(5) statistical method
Result represents with mean ± SEM, adopts SPSS 19.0 statistical software to carry out statistical analysis, otherness between comparative group.
(6) result
Give D-galactolipin and oral liquid 50 days, each group Mice Body weight average increases, and respectively organizes there was no significant difference.The heavy comparatively control group of brain of model group mouse obviously reduces.After group of taking medicine gives various dose oral liquid, brain heavily increases, especially with middle dosage group obviously (P<0.05).Mouse Y maze learning Memory result obviously reduces, and shows that D-galactolipin can make the learning and memory resolving ability of mouse obviously decline, and after giving oral liquid, the learning and memory raise marks of mouse obviously (P<0.05).The learning memory injury of its prompting oral liquid to D-galactolipin induced mice has protective effect, and middle dosage group even can meet or exceed levels found in normal controls, the results are shown in Table 1.Table 1 mouthful
Take the impact of liquid on mouse aging learning and memory achievement
| Group | n | Accuracy (%, mean ± SEM) |
| Normal group | 10 | 60.72±3.87 |
| Model group | 10 | 42.73±2.53 ### |
| Oral liquid group (25mg/kg) | 10 | 55.10±1.73* |
| Oral liquid group (50mg/kg) | 10 | 62.99±4.25*** |
| Oral liquid group (100mg/kg) | 10 | 59.78±3.81** |
Oral liquid is on the impact of mouse aging brain tissue SOD, MDA content: after giving D-galactolipin, and the SOD in mouse brain is active obviously to decline, and MDA content increases.The SOD that the oral liquid simultaneously giving various dose can significantly improve in brain tissue is active, reduces MDA content (P<0.05), the results are shown in Table 2.
Table 2 oral liquid is on the impact of mouse aging brain tissue biochemical indicator
Confirmatory experiment four: oral liquid white-skinned face function human experimentation
(1) tested object
Experimenter for the mean age be the student enrollment of 23 years old, wherein boy student 20, schoolgirl 16, totally 36.Adopt blind contrived experiment, experimenter be divided into two groups at random, one group as blank group, another group takes group as oral liquid.All experimenters are the healthy skin person affecting result judgement without erythema or pigmented spots etc.
(2) method of testing
Distance palm base portion 10 centimeters inside experimenter's left arm is selected to be experimental test position.First the melanin content before the black pigment of skin and the oral oral liquid in ferroheme tester determination experiment position is used.Survey five times, average for often.
Group of taking medicine to take night and morning oral liquid every day, and blank group to take night and morning placebo solution every day, and duration of test experimenter can not take other any cosmetics or oral drugs.
Experimenter is using oral liquid one week, two weeks, three weeks, surrounding continuously, after five weeks, six weeks, seven weeks and eight weeks, is using the black pigment of skin and ferroheme tester to measure the changing condition of skin color.
Statistics experimenter tests the numerical value that position records at every turn, analyzes its black pigment of skin and ferroheme Changing Pattern in table 3 and Fig. 3.As can be seen from Figure 3, oral oral liquid group melanin content is all on the low side compared with blank group, and continuing along with Time of Administration, has the trend reduced gradually, illustrates that oral liquid has good white-skinned face function.
Table 3 experimenter melanocyte variation tendency
| Group | One week | Two weeks | Three weeks | Surrounding | Five weeks | Six weeks | Seven weeks | Eight weeks |
| Blank group | 188.76 | 187.83 | 190.95 | 187.84 | 186.92 | 185.58 | 188.29 | 187.21 |
| Take oral liquid group | 185.13 | 182.32 | 180.31 | 179.25 | 178.59 | 178.02 | 177.35 | 176.89 |
The present invention is set forth by preferred embodiment; related personnel obviously can not depart from content of the present invention, spirit and scope method as herein described is changed or suitably change with combination; realize and apply the technology of the present invention; but this elaboration does not have limitation; if those skilled in the art or researcher enlighten by it; when not departing from the invention aim; adopt other similar components or method; suitable improving technique parameter realizes; without the technical scheme that performing creative labour obtains, protection scope of the present invention all should be belonged to.
Claims (2)
1. there is a health care oral liquid for whitening and delaying senility function, it is characterized in that, comprise following component and the mass percentage of each component is respectively:
Glabridin: 0.5 ~ 1%;
Epigallo-catechin gallate (EGCG): 0.5%-1%;
Natrium citricum: 0.05 ~ 0.15%;
Citric acid: 0.2 ~ 0.4%;
Honey: 8 ~ 12%;
Sucrose: 4%;
Sodium Benzoate: 0.05%;
Deionized water: surplus.
2. a kind of preparation method with the health care oral liquid of whitening and delaying senility function according to claim 1, is characterized in that, comprise the following steps:
(1) mix: by glabridin: 0.5 ~ 1%; Epigallo-catechin gallate (EGCG): 0.5%-1%; Natrium citricum: 0.05 ~ 0.15%; Citric acid: 0.2 ~ 0.4%; Honey: 8 ~ 12%; Sucrose: 4%; Sodium Benzoate: 0.05%; Deionized water: after surplus mixing, stir, and by homogenizer homogeneous;
(2) filling: by filling according to the amount of every bottle of 10ml for the mixture liquid after step (1) homogeneous;
(3) sterilization: after the liquid after filling for step (2) is adopted pasteurize, keep 40min under the temperature conditions of 70 ~ 80 DEG C after, obtain the health care oral liquid with whitening and delaying senility function.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410348555.5A CN104095236B (en) | 2014-07-21 | 2014-07-21 | A kind of have health care oral liquid of whitening and delaying senility function and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410348555.5A CN104095236B (en) | 2014-07-21 | 2014-07-21 | A kind of have health care oral liquid of whitening and delaying senility function and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104095236A CN104095236A (en) | 2014-10-15 |
| CN104095236B true CN104095236B (en) | 2015-09-30 |
Family
ID=51664069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410348555.5A Active CN104095236B (en) | 2014-07-21 | 2014-07-21 | A kind of have health care oral liquid of whitening and delaying senility function and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104095236B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104800207A (en) * | 2015-04-15 | 2015-07-29 | 江苏天晟药业有限公司 | Traditional Chinese medicine composition for improving memory as well as preparation method and application of traditional Chinese medicine composition |
| CN108785299A (en) * | 2017-04-28 | 2018-11-13 | 江苏康缘药业股份有限公司 | Glabridin is preparing the application in treating thrombotic diseases drug |
| CN110786329B (en) * | 2019-11-20 | 2021-06-08 | 中国农业科学院茶叶研究所 | Functional preparation for improving strawberry gray mold resistance and preparation method and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2263481A1 (en) * | 2009-05-29 | 2010-12-22 | Nestec S.A. | Green tea extracts of improved bioavailability |
| CN103371389B (en) * | 2012-04-19 | 2015-05-06 | 日加满饮品(上海)有限公司 | Preparation method for carbonated beverage containing cranberry nutrients |
| CN103520013A (en) * | 2012-07-04 | 2014-01-22 | 江苏天晟药业有限公司 | Skin-whitening and freckle-removing formula and preparation method for gel thereof |
-
2014
- 2014-07-21 CN CN201410348555.5A patent/CN104095236B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104095236A (en) | 2014-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8017162B2 (en) | Anti-inflammatory agent | |
| Mohd Effendy et al. | The effects of tualang honey on bone metabolism of postmenopausal women | |
| EP3643295A1 (en) | Composition containing cirsium japonicum extract as active ingredient for stimulating melanogenesis | |
| TW200843726A (en) | Agent for relief or prevention of xerostomia | |
| CN104095236B (en) | A kind of have health care oral liquid of whitening and delaying senility function and preparation method thereof | |
| EP2599490A1 (en) | Anti-fatigue composition, formulation and use thereof | |
| CN102083424A (en) | Methods and use of inducing apoptosis in cancer cells | |
| KR101908978B1 (en) | A aromatic composition having anti-stress and fatigue relaxing, and a cosmetic composition containing the same | |
| KR20200063855A (en) | A composition for promoting melanin synthesis comprising flower extract of milk thistle | |
| CN102578588A (en) | Combiner capable of promoting movement function and sexual function | |
| EP2859896A1 (en) | Pharmaceutical compositions for the treatment of muscular disorders | |
| Hasan et al. | Antibreast cancer activity of nanopropolis Indonesia on induced mammary gland tumor by dmba in virgin sprague-dawley rats | |
| CN109846907A (en) | Dermatological compositions containing Escherichia coli and enterococcus faecalis | |
| CN111936133A (en) | Pharmaceutical composition, excipient for the composition and use of the composition | |
| JP7130635B2 (en) | Composition for preventing and/or ameliorating brain dysfunction containing luteins or salts thereof and a processed product of a plant belonging to the genus Mercury | |
| KR101115502B1 (en) | The composition for prevention and treatment of hypersensitive skin disease containing Plantago asiatica Extract as an active ingredient | |
| CN101657201A (en) | The neuroblast proliferation promoter and the neurite outgrowth promoter | |
| KR20070103173A (en) | A composition for skin-care comprising coenzyme q10 | |
| CN106573026A (en) | Composition containing danpung bean leaf extract | |
| CN105477100A (en) | Lucid ganoderma spore oil compound health care spray and preparation method | |
| CN109276688B (en) | Traditional Chinese medicine composition for senile dementia | |
| JP2010270021A (en) | Ucp gene expression-promoting agent | |
| CN110269926A (en) | Middle benefit gas, which is relaxed, warms up composition and its preparation method and application | |
| Kim et al. | Repeated dose 90-day oral toxicity of Kaolin in Spraque-Dawley (SD) rats | |
| Ryu et al. | Establishment of advanced multi-organoid model based on functional characteristics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 212415 Jurong city of Jiangsu province Baohua Town Development Zone No. 10 Patentee after: Jiangsu Tiansheng Pharmaceutical Co., Ltd. Address before: 212415 Zhenjiang city of Jiangsu province Jurong Baohua Development Zone No. 10 Patentee before: Jiangsu Tiansheng Pharmaceutical Co., Ltd. |
|
| CP03 | Change of name, title or address |